AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05324462 — intervention group
Intervention type: DRUG
Intervention: IDegLira
Description: Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
Study NCT05826639 — intervention group
Intervention type: PROCEDURE
Intervention: Temperature-sensitive radiofrequency ablation
Description: Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
Study NCT05826639 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05160181 — intervention group
Intervention type: OTHER
Intervention: Yogatherapy
Description: Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
Study NCT04827407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon LPS hemoperfusion
Description: Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
Study NCT05554133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Microendoscope (HRME)
Description: The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
Study NCT05554133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Mapping Scope
Description: The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
Study NCT05554133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine hemisulfate
Description: A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
Study NCT06157515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-actuated vibrating mesh nebulizer
Description: The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
Study NCT06157515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous vibrating mesh nebulizer
Description: When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
Study NCT04973449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: 10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
Study NCT06453785 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Promaxo portable MRI
Description: The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel truly open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies.
Study NCT04973449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD2816
Description: 10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
Study NCT04969939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
Description: NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study NCT04969939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide 2.4 mg and placebo 2.0 mg
Description: NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study NCT04969939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
Description: NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study NCT04969939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide 2.4 mg and placebo 1.0 mg
Description: NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
Study NCT05452486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: English APD assessment
Description: Materials presented in English
Study NCT05452486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spanish APD assessment
Description: Materials presented in Spanish
Study NCT04699864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening of DR and DME with artificial intelligence using NeoRetina
Description: Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
Study NCT04699864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine ophthalmological evaluation of DR and DME
Description: Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
Study NCT04699864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos
Description: Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
Study NCT05546853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
Study NCT05546853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
Study NCT05546853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
Study NCT05546853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium levofolinate
Description: Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
Study NCT05546853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
Study NCT06250205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: oral administration
Study NCT06250205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
Description: oral administration
Study NCT06250205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone / Ethinyl Estradiol (COC)
Description: oral administration
Study NCT04261244 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative radiotherapy
Description: preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
Study NCT04261244 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative radiotherapy
Description: postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
Study NCT04711746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood sample withdrawal in order to perform DNA sequencing
Study NCT04711746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sample withdrawal in order to perform DNA sequencing
Study NCT06151288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 31 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of VAX-31 will be administered into the deltoid muscle at Day 1
Study NCT06151288 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Study NCT06065449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV).
Study NCT05511415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin solution, 20nM concentration
Study NCT05511415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (10-9M to 10-4M)
Study NCT06559696 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: internal mammary nodal irradiation
Description: chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
Study NCT06559696 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No internal mammary node irradiation
Description: chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
Study NCT06339099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
Study NCT06339099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
Study NCT06339099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loaded gait training
Description: An extra weight was added around the distal legs during gait training in the intervention group. This weight began at 0.5 kg and was gradually increased every two weeks to a maximum of 2 kg
Study NCT06347705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2141-V11 Antibody
Description: 2141-V11 Antibody: Intratumor injection
Study NCT05713630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: GD-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo. Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.
Study NCT05713630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg consisting of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 mg/mL solution for injection via intravenous (IV) consisting of 0.9% sodium chloride (saline).
Study NCT04058717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Nicotine Content research cigarettes
Description: Research cigarettes with 11.6 mg nicotine/cigarette.
Study NCT04058717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Nicotine e-cigarette
Description: E-cigarette containing high nicotine e-liquid
Study NCT04058717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content research cigarettes
Description: Research cigarettes with 0.2 mg nicotine/cigarette.
Study NCT04058717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Nicotine e-cigarette
Description: E-cigarette containing zero nicotine e-liquid
Study NCT05975840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 1
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
Study NCT05975840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03B
Description: Participants receive two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
Study NCT05975840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03A
Description: Participants receive two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
Study NCT05975840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 2
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 2 vaccine by intramuscular injection in the non dominant arm.
Study NCT05226624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rooming-in care
Description: Implementation of Rooming-in model of care
Study NCT05226624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline standard of care
Description: Baseline standard of care
Study NCT05891379 — intervention group
Intervention type: DRUG
Intervention: Inebilizumab
Description: Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
Study NCT05891379 — intervention group
Intervention type: DRUG
Intervention: oral immunosuppressant
Description: Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
Study NCT04780061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU
Description: This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
Study NCT04780061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C/Zinc
Description: This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
Study NCT04780061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2/D
Description: This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
Study NCT04780061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose Capsule
Description: Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
Study NCT04780061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglyceride Oil
Description: Placebo equivalent of Vitamin K2/D
Study NCT04782713 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Completing surveys
Description: Completing surveys at baseline, 3, 6, 9, and 12 months
Study NCT06585098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: game based learning
Description: The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher.
Study NCT06295185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application MARO
Description: It is a mental healthcare application aim to improve mental health.
Study NCT06295185 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham application
Description: It is a sham application in order to control spill over bias.
Study NCT05279196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps microbiopsy and blood collection
Description: Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program
Study NCT06362824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De Pie Intervention
Description: Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.
Study NCT06362824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)
Description: Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
Study NCT06585397 — intervention group
Intervention type: OTHER
Intervention: Grup 1
Description: Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
Study NCT05881304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized research e-cigarette (SREC)
Description: Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
Study NCT05881304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized research e-cigarette (SREC)
Description: Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.